Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29263630 | 0.95 | DRD2 (0.62) | DRD2TDP1MAOAMAOBSIGMAR1 | |
| SCHEMBL4572542 | 0.94 | DRD2 (0.60) | DRD2TDP1MAOAMAOBSIGMAR1 | |
| SCHEMBL8254760 | 0.93 | DRD2 (0.64) | DRD2TDP1SIGMAR1MEN1GAA | |
| SCHEMBL18604600 | 0.92 | DRD2 (0.58) | DRD2TDP1MAOAMAOBSIGMAR1 | |
| SCHEMBL31465614 | 0.92 | DRD2 (0.58) | DRD2TDP1MAOAMAOBSIGMAR1 | |
| SCHEMBL31596990 | 0.91 | DRD2 (0.58) | DRD2TDP1MAOAMAOBSIGMAR1 | |
| SCHEMBL30737178 | 0.90 | DRD2 (0.60) | DRD2TDP1MAOAMAOBSIGMAR1 | |
| SCHEMBL30572390 | 0.90 | DRD2 (0.57) | DRD2TDP1MAOAMAOBSIGMAR1 | |
| SCHEMBL24913972 | 0.90 | DRD2 (0.57) | DRD2TDP1MAOAMAOBSIGMAR1 | |
| SCHEMBL829444 | 0.90 | DRD2 (0.58) | DRD2TDP1MAOAMAOBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312217-A1 | Organic Compounds | TRPA1, TRPV1, CHRM1 | DRD2 1346/4885TDP1 2717/4885MAOA 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.